Lu, Kun Ping (Beth Israel Deaconess Medical Center)
Boxer, Matthew (NCATS)
Simeonov, Anton (NCATS)
Davis, Mindy (NCATS)
Pragani, Rajan (NCATS)
Shen, Min (NCATS)
Wei, Shuo (Beth Israel Deaconess Medical Center)
Zhou, Xiao Zhen (Beth Israel Deaconess Medical Center)
This technology includes the compositions and methods for inhibiting PIN1 for the treatment of disorders characterized by elevated PIN1 levels (e.g., immune disorders, proliferative disorders, and neurodegenerative disorders) with small molecules. Pin1 dysregulation has been associated with a number of pathological conditions. In particular, PIN1 has been shown to promote oncogenesis by modulating several oncogenic signaling pathways and its overexpression has been shown to correlate with poor clinical outcome. There are no current drug-like small molecule inhibitors of PIN1 that could be used therapeutically.
Inhibitors of PIN1 could be used to treat diseases such as: immune disorders, proliferative disorders, and neurodegenerative disorders.
There are currently no drug-like small molecule inhibitors of PIN1.